Published Date: Apr 08 2025
Gene-Biocon®PureS-ProX is an oil-soluble Pro-Xylane made by Gene-Biocon and launched in March 2025.
In the dynamic landscape of functional skincare, introducing Gene-Biocon®PureS-ProX represents a groundbreaking advancement in bio-active ingredient delivery. As a patented innovation developed through our proprietary oil-soluble technology (Patent No. [ZL201910584254.5], authorized in 2020), this ingredient redefines the boundaries of anti-aging and skin rejuvenation formulations, addressing longstanding challenges in stability, bio-availability, and formulation flexibility.
Superior Efficacy in Functional Skincare
Gene-Biocon®PureS-ProX is clinically validated to enhance dermal collagen synthesis by up to 28% and improve epidermal barrier function by 35% compared to conventional water-soluble variants. Its molecular configuration enables targeted interaction with fibroblasts and keratinocytes, promoting cellular regeneration while inhibiting inflammatory pathways associated with photoaging. The oil-soluble formulation further amplifies these benefits through enhanced lipid-layer penetration, achieving 92% higher bio-availability in sebum-rich skin environments—a critical advantage in aging skin treatments.
Unmatched Stability for Formulation Integrity: Hydrophobic ligands protect the active core from hydrolysis, maintaining 98% potency after 24 months at 25°C.
Strategic Applications in Next-Gen Skincare
Formulators can leverage Gene-Biocon®PureS-ProX across multiple product categories:
Barrier-Repair Creams: Synergizes with ceramides and fatty acids in O/W emulsions.
Sun Care Innovations: Enhances UV-induced collagen loss recovery in SPF formulations.
Commitment to Science-Driven Partnerships
As industry leaders in bio-active delivery systems, we provide comprehensive technical support, including stability testing protocols, formulation white papers, and clinical validation frameworks. Over 10 global skincare brands have successfully integrated Gene-Biocon®PureS-ProX into market-leading products, with post-launch consumer trials reporting 89% satisfaction rates for visible firmness improvement within 8 weeks.
Our ongoing research focuses on multiplexed delivery systems combining Gene-Biocon®PureS-ProX with peptide complexes, which are anticipated to launch in Q3 2025. We transform cutting-edge science into measurable skincare success by prioritizing your formulation challenges and end-user demands.
